Decision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict
- 1Department of Urogynaecology, King’s College Hospital, Denmark Hill, London, SE5 9RS UK
Abstract
Background: Refractory overactive bladder (OAB) lacks formal definition and is poorly understood. Its management requires patients to choose an invasive treatment, including intravesical botulinum toxin A (BOTOX®), sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS), which have varying rates of efficacy and side effects. These decisions can be complex for patients to make, especially within the time constraints of outpatient clinic appointments. A new patient decision aid (PDA) has been developed to support patients during this shared decision-making process.
Aim: This study assesses decisional conflict scores and patient satisfaction in those who use a novel PDA for refractory OAB.
Methods: Consecutive new patients with refractory OAB were provided with the PDA prior to decision-making. Patients then had a virtual follow-up appointment to assess their decisional conflict, using a validated scale. The total decisional conflict score was calculated. Treatment choice and free-text feedback were also analysed.
Results: Twenty-five patients were included. Following use of the PDA, a range of treatment choices were made, including SNM (n = 6), PTNS (n = 10), BOTOX® (n = 6) and continuation with medical therapy (n = 3). Overall, decisional conflict was low, with 100% of patients having a score of less than 25. Subscores suggested improved patient understanding, with the PDA increasing clarification.
Conclusion: Introduction of this novel PDA, in those requiring treatment for refractory OAB, was associated with low decisional conflict and positive patient feedback. This supports its use in shared decision-making, empowering patients to make an informed and individualised choice regarding their treatment.
Related
- eHealth literacy and decisional conflict in patients with coronary heart disease: chain mediation of cyberchondria and psychological inflexibility and a latent profile analysis
- Case Report: Longitudinal evaluation of cerebrospinal fluid Alzheimer’s disease core biomarkers in a case of refractory late-onset epilepsy of unknown etiology
- Beyond the Sagittal Plane: The Lateral Countermovement Jump as a Clinical Tool for Return-to-Play Decision-Making and Performance Evaluation
- Real-world evaluation of a multilingual agentic retrieval-augmented clinical AI framework for evidence-grounded medical decision support
- A Transparent Rule-Based Decision-Support Prototype for Diabetic Menu Planning and Meal-Combination Optimization: Development and Computational Evaluation
BibTeX
@article{mohamedahmed2026decisionmaking,
title = {{Decision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict}},
author = {Rayan Mohamed-Ahmed and Angie Rantell and Annika Taithongchai and George Araklitis and Dudley Robinson},
journal = {International Urogynecology Journal},
year = {2026},
month = may,
doi = {10.1007/s00192-026-06688-3},
url = {https://doi.org/10.1007/s00192-026-06688-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Decision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict
AU - Rayan Mohamed-Ahmed
AU - Angie Rantell
AU - Annika Taithongchai
AU - George Araklitis
AU - Dudley Robinson
PY - 2026
DA - 2026/05/19
JO - International Urogynecology Journal
DO - 10.1007/s00192-026-06688-3
UR - https://doi.org/10.1007/s00192-026-06688-3
AB - Background: Refractory overactive bladder (OAB) lacks formal definition and is poorly understood. Its management requires patients to choose an invasive treatment, including intravesical botulinum toxin A (BOTOX®), sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS), which have varying rates of efficacy and side effects. These decisions can be complex for patients to make, especially within the time constraints of outpatient clinic appointments. A new patient decision aid (PDA) has been developed to support patients during this shared decision-making process. Aim: This study assesses decisional conflict scores and patient satisfaction in those who use a novel PDA for refractory OAB. Methods: Consecutive new patients with refractory OAB were provided with the PDA prior to decision-making. Patients then had a virtual follow-up appointment to assess their decisional conflict, using a validated scale. The total decisional conflict score was calculated. Treatment choice and free-text feedback were also analysed. Results: Twenty-five patients were included. Following use of the PDA, a range of treatment choices were made, including SNM (n = 6), PTNS (n = 10), BOTOX® (n = 6) and continuation with medical therapy (n = 3). Overall, decisional conflict was low, with 100% of patients having a score of less than 25. Subscores suggested improved patient understanding, with the PDA increasing clarification. Conclusion: Introduction of this novel PDA, in those requiring treatment for refractory OAB, was associated with low decisional conflict and positive patient feedback. This supports its use in shared decision-making, empowering patients to make an informed and individualised choice regarding their treatment.
SN - 0937-3462
SN - 1433-3023
ER -